Overview

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

Status:
Completed

Trial end date:
2004-02-01

Target enrollment:

Participant gender:

Summary

A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder

Phase:

Phase 4

Details

Lead Sponsor:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborator:

Janssen, LP

Treatments:

Antipsychotic Agents
Quetiapine Fumarate
Risperidone